However, elderly ACS patients are less likely to receive evidence-based treatment, including revascularization therapy, due to uncertainty of the associated benefits and risks in this population. This article addresses key issues regarding medical and revascularization therapy in elderly ACS find more patients based on a review of the medical literature and in concordance with clinical practice guidelines from the American Heart Association (AHA) and the American College of Cardiology (ACC).”
“In the present study, the anti-atopic effect of phosphatidylserine (PS) extracted from soybean was investigated in NC/Nga
mice. The atopic symptoms were evaluated by scoring spontaneous scratching behavior and skin lesions, by measuring serum levels of immunoglobulin E (IgE) and interleukin-4 (IL-4), and by observing skin histology. After observing the maximum severity of atopic symptoms, PS was initiated. The PS treatment significantly alleviated apparent symptoms of atopic dermatitis and scratching behavior. The suppression of atopic dermatitis by PS was verified by decreases in the serum levels of IgE (p<0.05 after 8 weeks;
p<0.001 after 9 weeks) and IL-4 (p<0.01 after 7 weeks; p<0.001 after 9 weeks). Histological observations also indicated that the thickening process of skin and the infiltration of inflammatory cells see more were significantly inhibited. Taken together, PS from soybean might be useful for alleviating atopic dermatitis symptoms and thus for developing a new medicine for treating human atopic disease.”
“Background: There is limited evidence to support the efficacy of current pharmaceutical agents in reducing Angiogenesis inhibitor the risk of hip fracture in older postmenopausal women with established osteoporosis.
Objective: To clarify the efficacy of risedronate in reducing the risk of hip fracture in elderly postmenopausal women aged. 70 years with established osteoporosis, i.e., those with bone mineral density-defined osteoporosis and a prevalent vertebral fracture.
Methods: Post hoc analysis
of the Hip Intervention Program (HIP) study, a randomized controlled trial comparing risedronate with placebo for reducing the risk of hip fracture in elderly women. Women aged >= 70 to 100 years with established osteoporosis (baseline femoral neck T-score <= -2.5 and. >= 1 prior vertebral fracture) were included. The main outcome measure was 3-year hip fracture incidence in the risedronate and placebo groups.
Results: A total of 1656 women met the inclusion criteria. After 3 years, hip fracture had occurred in 3.8% of risedronate-treated patients and 7.4% of placebo-treated patients (relative risk 0.54; 95% confidence interval 0.32-0.91; P = 0.019).
Conclusion: Risedronate significantly reduced the risk of hip fracture in women aged up to 100 years with established osteoporosis.